A Dose-Ranging Study of the Efficacy of ABT-894 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Completed · Phase 2 · Has a placebo group

Conditions studied: Attention-Deficit/Hyperactivity Disorder, ADHD

In brief

A Dose-Ranging Study of the Efficacy of ABT-894 in Adults with Attention-Deficit/Hyperactivity Disorder (ADHD)

Key facts

Study ID

NCT00429091

Run by

Abbott

People needed

243

Starts

2007-01-01

Last updated by the study team

2010-11-02

Who can join

Age: 18 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet criteria for attention-deficit/hyperactivity disorder
• Have voluntarily signed an informed form
• Are between 18 and 60 years of age
• Will use contraceptive methods during the study
• Women must not be pregnant or breast-feeding
• Must be in generally good health
• Are fluent in English

You may not qualify if…

• They have a current or past diagnosis of schizoaffective disorder, schizophrenia, obsessive-compulsive disorder, drug-induced psychosis, bipolar disorder, psychotic disorder or mental retardation
• They have a current diagnosis of major depressive episode, generalized anxiety disorder (GAD), or post-traumatic stress disorder (PTSD) or has a clinically significant sleep disorder requiring treatment
• They require ongoing treatment or expected treatment with any psychotropic medication, including anxiolytics, antipsychotics, anticonvulsants, antidepressants, mood stabilizers, nicotine replacement therapies or varenicline
• They require ongoing treatment or expected treatment with Coumadin
• They failed to respond to two or more adequate trials of FDA-approved ADHD medication
• They have taken atomoxetine during the last 3 months
• They have violent, homicidal or suicidal ideation
• They have a significant history of medical diagnoses, seizure disorder, Tourette's syndrome, traumatic brain injury, or a central nervous system (CNS) disease, excluding ADHD
• They have a urine drug screen that is positive for alcohol or drugs of abuse
• They have a history of substance or alcohol disorder during the last 3 months

Where it is running

• Site Reference ID/Investigator# 5965 — San Francisco, California, United States
• Site Reference ID/Investigator# 5955 — Wildomar, California, United States
• Site Reference ID/Investigator# 5974 — Orlando, Florida, United States
• Site Reference ID/Investigator# 5956 — West Palm Beach, Florida, United States
• Site Reference ID/Investigator# 5973 — Libertyville, Illinois, United States
• Site Reference ID/Investigator# 5968 — Overland Park, Kansas, United States
• Site Reference ID/Investigator# 5952 — Rockville, Maryland, United States
• Site Reference ID/Investigator# 5962 — Boston, Massachusetts, United States
• Site Reference ID/Investigator# 5954 — Okemos, Michigan, United States
• Site Reference ID/Investigator# 5970 — Troy, Michigan, United States
• Site Reference ID/Investigator# 5960 — Clementon, New Jersey, United States
• Site Reference ID/Investigator# 5963 — Charlotte, North Carolina, United States
• Site Reference ID/Investigator# 5975 — Eugene, Oregon, United States
• Site Reference ID/Investigator# 5971 — Philadelphia, Pennsylvania, United States
• Site Reference ID/Investigator# 5957 — Charleston, South Carolina, United States
• Site Reference ID/Investigator# 5972 — Austin, Texas, United States
• Site Reference ID/Investigator# 5959 — Bellaire, Texas, United States
• Site Reference ID/Investigator# 5969 — San Antonio, Texas, United States
• Site Reference ID/Investigator# 5951 — Salt Lake City, Utah, United States
• Site Reference ID/Investigator# 5964 — Burlington, Vermont, United States
• Site Reference ID/Investigator# 5953 — Virginia Beach, Virginia, United States
• Site Reference ID/Investigator# 5958 — Bellevue, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.